Skip to main content
ALLOAllogene Therapeutics, Inc.Hold3.8·$0.63
HoldHigh Confidence
Investment thesis

Allogene has beaten earnings in 3 straight quarters, but sub-floor quality driven by cash burn and no moat, value-trap margin and leverage signals, justified elevated short interest, and a rejected, implausible analyst price target all argue for treating the stock's headline upside with skepticism.

Thesis pillars

  • Value Trap Margin Leverage↑Improving
  • Perfect Earnings Beat Streak↓Deteriorating
  • Sub Floor Quality Cash Burn→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 12, 2026· older than 90 days

Full reasoning →

Open full analysis

Allogene Therapeutics, Inc. (ALLO) Stock Analysis

Falling Knife setup

HoldVALUE-TRAP 2/5ValueQualityShortHigh Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $0.63, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329); DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP..

Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell therapies for cancer and autoimmune disease, anchored by three core programs: cema-cel for first-line large B-cell lymphoma, ALLO-329 for autoimmune disease, and... Read more

$0.63+115.1% Upside to targetScore 3.8/10#235 of 240 Biotechnology
QualityF-score4 / 9FCF yield-31.07%
Stop $0.60Resistance target $1.35A.R:R 0.0:1
Analyst consensus$9.00+1333.8%9 analysts with price targets
$1.35Resistance target
$0.63price
$9.00mean
$14

Hold if already holding. Not a fresh buy at $0.63, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329); DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP.. Chart setup: Death cross, below all MAs, RSI 18, MACD bearish. Market cap $217M below $400M minimum. Not in investable universe. Score 3.8/10, high confidence.

Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 109d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 20, 2026
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 11, 2027109d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329)
DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP.
Market cap $217M below $400M minimum

Key Metrics

P/E (TTM)—
P/E (Fwd)-1.1
Mkt Cap$217M
EV/EBITDA-0.0
Profit Mgn0.0%
ROE-49.3%
Rev Growth—
Beta0.78
DividendNone
Analysts with ratings18

Quality Signals

Piotroski F4/9

Options Flow

P/C0.33bullish
IV341%elevated

Concentration Risks(10-K Item 1A)

  • HIGHpipelinelead product candidates (cema-cel, ALLO-316, ALLO-329)
    10-K Item 1A: 'Our business is highly dependent on the success of our lead product candidates.'

Material Events(8-K, last 90d)

  • 2026-05-28Item 5.02MEDIUM
    President and CEO David Chang will depart effective June 30, 2026, replaced by Zachary Roberts, M.D., Ph.D. (currently EVP R&D and CMO) effective July 1, 2026; Roberts also joins the Board as a Class I director. Chang is eligible for severance under the company's Change in Control and Severance Benefit Plan. No disagreement cited.
    SEC filing →
  • 2026-05-13Item 1.02MEDIUM
    Allogene terminated its December 2020 Exclusive License Agreement with Overland Therapeutics covering allogeneic CAR T therapies (BCMA, CD70, FLT3, DLL3) in Greater China, Taiwan, South Korea, and Singapore, entering a new Shareholders' Agreement with Overland and HH BioPharma Holdings. Allogene had received a $40.0 million upfront payment and $79.0 million in Overland preferred stock under the terminated agreement.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Expensive valuation
Low model confidence on this dimension (20%).

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.2
Cash-burning: FCF -1456% of revenueNo competitive moatQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.9
Obv
1.0
Ma Position
1.0
Rsi
3.0
Macd
3.5
Capitulation risk (RSI 18, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope -3.5%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
1.1
Quality Rank
2.6
Growth Rank
5.0
GatesMomentum 1.9<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Executive change: officer departure/appointmentInsider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 109d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
18 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $0.62Resistance $1.38

Price Targets

$1
$1
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP.
! Market cap $217M below $400M minimum
! Value-trap signals (2/5): Margin compression (op margin -42.1%), Material insider selling (116 sells, 2.32% of cap)

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-03-11 (109d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ALLO stock a buy right now?

Hold if already holding. Not a fresh buy at $0.63, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329); DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP.. Chart setup: Death cross, below all MAs, RSI 18, MACD bearish. Market cap $217M below $400M minimum. Not in investable universe. Resistance target $1.35 (+115.1%), stop $0.60 (−4.6%), A.R:R 0.0:1. Score 3.8/10, high confidence.

What is the ALLO stock price target?

Resistance target: $1.35 (+115.1% upside). Resistance target $1.35 (+115.1%), stop $0.60 (−4.6%), A.R:R 0.0:1. Stop-loss: $0.60.

What are the risks of investing in ALLO?

Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329); DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $0.63 — ratio 14.3×). Rejected, falling back to technical TP.; Market cap $217M below $400M minimum.

Is ALLO overvalued or undervalued?

Allogene Therapeutics, Inc. trades at a P/E of N/A (forward -1.1). TrendMatrix value score: 0.0/10. Verdict: Hold.

What do analysts say about ALLO?

18 analysts rate ALLO, with a consensus score of 4.2/5. 9 analysts publish price targets averaging $9.

What does Allogene Therapeutics, Inc. do?Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell...

Allogene Therapeutics is a clinical-stage immuno-oncology company developing 'off-the-shelf' allogeneic CAR T cell therapies for cancer and autoimmune disease, anchored by three core programs: cema-cel for first-line large B-cell lymphoma, ALLO-329 for autoimmune disease, and ALLO-316 for renal cell carcinoma. The company has no product revenue, reported a $190.9 million net loss and $2.0 billion accumulated deficit for 2025, and licenses gene-editing technology from Cellectis (TALEN) and Arbor Biotechnologies (CRISPR).

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › ALLO

Latest news

Latest News

Fiscal.ai2d ago
Fiscal.ai13d ago
Benzinga13d ago
Benzinga17d ago
Fiscal.ai17d ago
Benzinga17d ago
Fiscal.ai19d ago
Benzinga19d ago
Fiscal.ai24d ago
Fiscal.ai27d ago
Benzinga69d agoProduct
Benzinga81d agoLeadership Change
Benzinga97d ago
Benzinga102d ago
Benzinga102d ago
Benzinga116d ago
Benzinga130d agoProduct